Quick answers
- What is Invega Hafyera?
- Invega Hafyera is a brand name of Paliperidone palmitate, a prescription medicine. The FDA NDC Directory lists 2 Invega Hafyera products in 2 strengths and forms.
- Who makes Invega Hafyera?
- Janssen Pharms holds the FDA application for Invega Hafyera (NDA207946, approved May 18, 2015).
- Is there a generic or store brand of Invega Hafyera?
- Other products of Paliperidone palmitate are listed with the FDA, but none in exactly the same strength and form as a Invega Hafyera product.
- What do pharmacies pay for Invega Hafyera?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 2 Invega Hafyera strengths and forms (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Invega Hafyera been recalled?
- No recall linked to Invega Hafyera products (by their NDC code or label) appears in the FDA enforcement reports we use.
What Invega Hafyera is
Each Invega Hafyera product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Paliperidone palmitate · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| paliperidone palmitate 1092 mg/3.5 mL injection, suspension, extended release (intramuscular) | Invega Hafyera | None listed | DailyMed |
| paliperidone palmitate 1560 mg/5 mL injection, suspension, extended release (intramuscular) | Invega Hafyera | None listed | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Paliperidone palmitate →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| NDA207946 | Janssen Pharms | May 18, 2015 | 2 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| paliperidone palmitate 1092 mg/3.5 mL injection, suspension, extended release | Brand: Invega Hafyera | $4,047.71 per mL |
| paliperidone palmitate 1560 mg/5 mL injection, suspension, extended release | Brand: Invega Hafyera | $4,233.40 per mL |
NADAC list of November 4, 2026; these prices took effect between January 2, 2026 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Invega Hafyera
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Invega Hafyera products.
- Janssen Pharmaceuticals, Inc2 products
Recalls
No recall linked to Invega Hafyera products (by their NDC code or label) appears in the FDA enforcement reports.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.